We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+16.37%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$26.2M
Cap. Flow
+$45.7M
Cap. Flow %
10.38%
Top 10 Hldgs %
36.84%
Holding
138
New
52
Increased
12
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$10.8M
2
INSM icon
Insmed
INSM
+$9.42M
3
BBIO icon
BridgeBio Pharma
BBIO
+$6.93M
4
APLS
Apellis Pharmaceuticals
APLS
+$5.77M
5
BCYC
Bicycle Therapeutics
BCYC
+$5.19M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$18.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.97M
4
BHVN icon
Biohaven
BHVN
+$6.93M
5
ETNB
89bio
ETNB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 53.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
101
X4 Pharmaceuticals
XFOR
$375M
$304K 0.07%
11,638
– –
AMLX icon
102
Amylyx Pharmaceuticals
AMLX
$2.26B
$293K 0.07%
+10,000
New +$347K
BIIB icon
103
Biogen
BIIB
$30B
$267K 0.06%
962
– –
PHXM
104
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$252K 0.06%
24,843
+24,541
+8,126% +$189K
CNTB
105
Connect Biopharma Holdings
CNTB
$127M
$219K 0.05%
219,501
– –
SYBX
106
DELISTED
Synlogic
SYBX
$194K 0.04%
20,450
– –
ARKK icon
107
ARK Innovation ETF
ARKK
$5.66B
$182K 0.04%
4,519
– –
RLMD icon
108
Relmada Therapeutics
RLMD
$557M
$148K 0.03%
65,491
– –
BLCM
109
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$148K 0.03%
448,101
– –
SPPI
110
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$133K 0.03%
176,980
– –
GNFT
111
DELISTED
Genfit
GNFT
$132K 0.03%
+32,786
New +$141K
STSA
112
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$95K 0.02%
136,059
– –
FNCH
113
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$93.4K 0.02%
7,918
– –
RCKTW icon
114
Rocket Pharmaceuticals Warrant
RCKTW
$149K
$60K 0.01%
+367,112
New +$70.8K
MDGL icon
115
Madrigal Pharmaceuticals
MDGL
$10.8B
$18.2K ﹤0.01%
75
– –
BGMS
116
Bio Green Med Solution Inc
BGMS
$4.91M
$11K ﹤0.01%
+76
New +$227K
GOSS icon
117
Gossamer Bio
GOSS
$82.9M
$7.69K ﹤0.01%
6,100
– –
ARVN icon
118
CALL
Arvinas
ARVN
$518M
– –
-100,000
Closed -$3.42M
ATXS
119
CALL
DELISTED
Astria Therapeutics
ATXS
– –
-171,100
Closed -$2.55M
BIIB icon
120
CALL
Biogen
BIIB
$30B
– –
-1,800
Closed -$498K
CABA icon
121
Cabaletta Bio
CABA
$437M
– –
-30,286
Closed -$280K
DSGN icon
122
CALL
Design Therapeutics
DSGN
$761M
– –
-800
Closed -$8.21K
DSGN icon
123
Design Therapeutics
DSGN
$761M
– –
-11,568
Closed -$119K
DSGN icon
124
PUT
Design Therapeutics
DSGN
$761M
– –
-48,500
Closed -$498K
ESPR
125
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-1,296,900
Closed -$8.08M
2 3 4
5
6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Ikarian Capital held 138 positions worth $441M, up 6.3% from $415M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital deployed $45.7M of net new capital in Q1 2023, opening 52 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 100,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 58% a quarter earlier.

On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $18.8M trimmed.

  • Ikarian Capital's largest Q1 2023 buy was Merck: 100,000 shares worth $10.6M.
  • Ikarian Capital added most to Altimmune in Q1 2023, an estimated $4.8M increase.
  • Ikarian Capital's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $18.8M.
  • Ikarian Capital fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $10.2M.
  • Ikarian Capital's ten largest holdings make up 37% of its $441M portfolio in Q1 2023.
  • Ikarian Capital opened 52 new positions and closed 21 in Q1 2023.
  • Ikarian Capital's portfolio value rose 6.3% quarter-over-quarter to $441M.

Based on Ikarian Capital's 13F filing for Q1 2023, filed 15 May 2023.